Winter Is Coming: What Can Novo Nordisk Do Next After Stock Fall?
Executive Summary
Change must be due for Danish diabetes giant Novo Nordisk as the firm continues to flounder in the US thanks to a tough pricing environment, increased competition for insulin products and supposed cultural differences between European and American management teams.